Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy: Histologic findings in eight patients from an open-label pilot study

Arthritis and Rheumatism

Volumn 44, Issue 1, 2001, Pages 186-195

  Baeten, Dominique ^a,b   Kruithof, Elli ^a   Van Bosch, Filip Den ^a   Demetter, Pieter ^a   Van Damme, Nancy ^a   Cuvelier, Claude ^a   De Vos, Martine ^a   Mielants, Herman ^a   Veys, Eric M ^a   De Keyser, Filip ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD20 ANTIGEN; CD3 ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DECAY ACCELERATING FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; NIMESULIDE; PHENYLBUTAZONE; PIROXICAM; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NEUTROPHIL; PRIORITY JOURNAL; SPONDYLOARTHROPATHY; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; JOINT DISEASES; PILOT PROJECTS; SPINAL DISEASES; SYNOVIAL MEMBRANE; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035150659     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B     Document Type: Article

References (48)

1. Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis
2. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis
3. Role of cytokines in rheumatoid arthritis
4. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
5. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis
6. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
7. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
8. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
9. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
10. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis
11. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
12. Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
13. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis
14. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis
15. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis
16. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis
17. Prevalence of clinical and subclinical spondyloarthropathy in patients with inflammatory bowel disease
18. Bowel inflammation and the spondyloarthropathies
19. Gut inflammation in the spondyloarthropathies: Clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study
20. Long term evolution of gut inflammation in patients with spondyloarthropathy
21. Crohn's disease associated with spondyloarthropathy: Effect of TNF-α blockade (infliximab) on the articular symptoms
22. Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation
23. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study
24. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
25. Needle arthroscopy of the knee with synovial biopsy sampling: Technical experience in 150 patients
26. Intraarticular variability of synovial membrane histology, immunohistology and cytokine mRNA expression in patients with rheumatoid arthritis
27. Distribution of T cells and signs of T-cell activation in the rheumatoid joint: Implications for semiquantitative comparative histology
28. A comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy and osteoarthritis: Influence of disease duration and activity
29. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis
30. Quantification of the cell infiltrate in synovial tissue by digital image analysis
31. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis
32. Intra-articular primatised anti-CD4: Efficacy in resistant rheumatoid knees: A study of combined arthroscopy, magnetic resonance imaging, and histology
33. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis
34. The effects of interferon-β treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis
35. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity
36. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab
37. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis
38. Synovial cytokine and growth factor regulation of MMPs/TIMPs: Implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients
39. Tumour necrosis factor α (TNF-α) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: A possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-α therapy for RA
40. Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis
41. Analysis of initial attachment of B cells to endothelial cells under flow conditions
42. Memory B lymphocytes from secondary lymphoid organs interact with E-selectin through a novel glycoprotein ligand
43. The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules
44. B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement
45. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5
46. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen
47. Regulation of B cell maturation and differentiation: Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF)
48. Molecular control of B lymphocyte growth and maturation